Bladder cancer
β Scribed by Donald L. Lamm
- Publisher
- John Wiley and Sons
- Year
- 1997
- Tongue
- English
- Weight
- 41 KB
- Volume
- 13
- Category
- Article
- ISSN
- 8756-0437
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
Intravesical therapy has been used in the management of superficial transitional cell carcinoma (TCC) of the urinary bladder (i.e., Ta, Tl, and carcinoma in situ) with specific objectives which include treating existing/residual tumor, preventing recurrence of tumor, preventing disease progression,
The CD40 receptor is expressed in many immune cell types and is known to play a central role in both humoral and T-cell-mediated immunity, being a subject of intense research interest in recent years. It is also expressed on a variety of carcinomas and may therefore be of biological significance in
The incidence of bladder cancer continues to increase, with an estimated 53,000 new cases diagnosed in the United States in 1996-90% of which are transitional cell carcinomas. The male-to-female ratio is 3:1. A number of etiological factors are associated with the development of bladder cancer, but